The Life Sciences sector includes companies involved in biopharmaceuticals, medical manufacturing and distribution, and bio products.
Valeo Pharma is a specialty pharmaceutical company dedicated to the commercialization of innovative prescription products in Canada. With a focus on neurodegenerative diseases, woman’s health and oncology, Valeo Pharma has a growing portfolio of innovative products and the proper infrastructure to manage these products through all stages of commercialization. Headquartered in Kirkland, Quebec, Valeo Pharma has all internal capabilities to register and market health care solutions for Canadian patients. For more information, please visit www.valeopharma.com
Vapen MJ Ventures Corporation, through its wholly-owned subsidiaries, currently operates as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing of THC and CBD cartridges, concentrates, edibles, retail dispensary, and wholesale distribution of high margin cannabis and CBD products. VAPEN MJ currently provides these management and marketing services in the State of Arizona with expansion plans through acquisitions and partnerships worldwide.
The Company’s mission is to enable licensed cultivators worldwide of cannabis and hemp to enhance quality and yields and to proliferate the VAPEN brand through their established channels.
Ventura Cannabis and Wellness (VCAN) is a vertically integrated, California-based products cannabis company. The Company is currently building out its distribution channel through revenue sharing agreements with owner-operator of cannabis dispensaries to ensure it’s products get premium shelf space. The Company plans to target four significant segments in the U.S. cannabis and CBD market with products suited to their needs: senior citizens, upwardly mobile middle-aged professionals and individuals suffering from addiction. These segments desire discrete and well-designed products as well as the accurate dosage of THC. The Company launched into the cannabis industry after a shareholder vote in April 2019 approving the change in business from addiction treatment to cannabis.
Veritas Pharma Inc. (trading symbol CSE:VRT) is an early stage pharmaceutical company developing innovative medicinal cannabis cultivars for specific disease conditions such as chronic pain, emesis (nausea/vomiting), and epilepsy. Using a ‘lean and mean’ approach to product development, the company aims to select candidate cultivars using classical pharmacology techniques and then immediately evaluate them in the clinic to maximize both the Company has applied to Health Canada for a medical marijuana production and distribution license under the Marihuana for Medical Purposes Regulations (the “MMPR“).
Vibe is a vertically integrated cannabis company whose mission is to become a dominant California cannabis retailer and multi-state operator. The Company delivers exceptional retail experiences with its ‘Vibe by California’ brand and ethos, premier cultivation product, and high-efficiency delivery and distribution. The Company’s management team brings expertise in retail, cannabis cultivation, and mergers and acquisitions to support its U.S. expansion through accretive acquisitions and organic growth.
Vireo is one of America's leading multi-state cannabis companies. Vireo is a physician-led, science-focused organization, dedicated to providing patients with best-in-class quality cannabis-based products and customer experience. Vireo cultivates cannabis in environmentally-friendly greenhouses, manufactures pharmaceutical-grade cannabis extracts, and sells its products at both company-owned and third-party dispensaries. Vireo currently has operations in ten states: Arizona, Maryland, Massachusetts, Minnesota, Nevada, New Mexico, New York, Ohio, Pennsylvania and Rhode Island, plus Puerto Rico.
In addition to the listed Subordinate Voting Shares, there are 563,032 Multiple Voting Shares and 65,411 Super Voting Shares issued and outstanding. Each Super Voting Share is convertible into one Multiple Voting Share at the option of the holder or upon certain triggering events. Each Multiple Voting Share is convertible into 100 Subordinate Voting Shares at the option of the holder or upon certain triggering events. This number also includes subordinate voting shares underlying existing and proposed convertible securities.
Vodis Pharmaceuticals Inc. is positioned to be among the first pharmaceutical corporations in Canada to produce and market medical marijuana under license from Health Canada in accordance with the existing Narcotic Control Regulations (“NCR”) and the new Marihuana for Medical Purposes Regulations (“MMPR”) that came into effect on April 1, 2014. Vodis filed its MMPR in August 2013 and in January 2014 received a ‘ready to build’ letter from Health Canada. IT IS CURRENTLY AWAITING FINAL INSPECTION FROM HEALTH CANADA. The company has been operating under the MMAR regulations at its 12,000 square foot production facility consisting of six rooms. This was recently upgraded to eight rooms consisting of between 40 and 50 lights per room. The estimated production when fully operational under the MMPR license is between 150-200 pounds per month of award-winning cannabis.
Each Cannabis Growth Opportunity Corp share purchase warrant entitles the holder to acquire one common share at a price of $2.50, subject to adjustment, on or prior to 5:00 p.m. (Toronto time) on the expiry date, January 26, 2020. The warrants are subject to an accelerated expiry should certain conditions be met. See the Warrant Indenture for a full description and terms of the warrants.
Wayland is a vertically integrated cultivator and processor of cannabis. The Company was founded in 2013 and is based in Burlington, Ontario, Canada and Munich, Germany, with production facilities in Langton, Ontario where it operates a cannabis cultivation, extraction, formulation, and distribution business under federal licenses from the Government of Canada. The Company also has production operations in Dresden, Saxony, Germany, Regensdorf, and Switzerland along with a joint venture in Allesandria, Piedmont, Italy. Wayland will continue to pursue new opportunities globally, including the consummation of its previously announced transactions in the United Kingdom, Australia, Colombia, and Argentina, in its effort to enhance lives through cannabis.